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INTRODUCTION
LIVER
The  liver  is  the  largest  organ  of  the  human  body  (Figure  1),  weighs 
approximately 1500 g, and is located in the upper right corner of the abdomen. 
The organ is closely associated with the small intestine. The liver performs over 
500 metabolic functions (Kumar et al. 2005). Almost all blood that enters the liver 
via  the  portal  tract  originates  from the  gastrointestinal  tract.  A  second  blood 
supply to the liver comes from the hepatic artery. The portal vein supplies venous 
blood under low pressure conditions to the liver, while the hepatic artery supplies 
high-pressured arterial blood. Since the capillary bed of the gastrointestinal tract 
already extracts most O2, portal venous blood has a low O2  content. Blood from 
the hepatic  artery on the other hand,  originates  directly from the aorta  and is, 
therefore, saturated with O2. Blood from both vessels joins in the capillary bed of 
the liver and leaves via central veins to the inferior caval vein.
Figure 1: The liver
  
The various functions of the liver:
• Breaks down toxic substances and most medicinal products in a process 
called drug metabolism. 
• Produces and excretes bile  required for emulsifying fats. 
• Role of liver in carbohydrate metabolism: 
Gluconeogenesis (the synthesis of glucose from certain amino acids, 
lactate or glycerol) 
Glycogenolysis (the breakdown of glycogen into glucose) 
Glycogenesis (the formation of glycogen from glucose)
• Produce and store proteins and regulate many substance involved in 
protein metabolism. 
• Breakdown of insulin and other hormones 
• The liver also performs several roles in lipid metabolism: Cholesterol 
synthesis, the production of triglycerides (fats). 
• Produces coagulation factors I (fibrinogen), II (prothrombin), V, VII, IX, 
X and XI, as well as protein C, protein S and antithrombin. 
• Converts ammonia to urea. 
• Stores a multitude of substances, including glucose (in the form of 
glycogen), vitamin B12, iron, and copper. 
• Produces albumin, the major osmolar component of blood serum. 
Drug Induced Liver Toxicity
Drug-induced  hepatotoxicity  is  a  frequent  cause  of  liver  injury.  The 
pathogenesis of drug-induced liver disease usually involves the participation of 
the parent drug or metabolites that either directly affect the cell biochemistry or 
elicit an immune response. (Kaplowitz 2004). 
Risk factors of drug induced hepatotoxicity: 
• Drug formulation: Long-acting drugs may cause more injury than shorter-
acting drugs.  
• Age: Apart from accidental  exposure, hepatic drug reactions are rare in 
children. Elderly persons are at increased risk of hepatic injury because of 
decreased  clearance,  drug-to-drug  interactions,  reduced  hepatic  blood 
flow, variation in drug binding, and lower hepatic volume
• Sex: Hepatic drug reactions are more common in females. 
• Alcohol  ingestion:  Alcoholic  persons  are  susceptible  to  drug  toxicity 
because alcohol induces liver injury and cirrhotic changes that alter drug 
metabolism.  Alcohol  causes  depletion  of  glutathione  (hepatoprotective) 
stores that make the person more susceptible to toxicity by drugs. 
• Genetic factors
• Other comorbidities: Persons with AIDS, persons who are malnourished, 
and persons who are fasting may be susceptible to drug reactions because 
of low glutathione stores. 
Many drugs have been withdrawal from the market mainly due to its liver 
toxicity in the course of its treatment. An enormous amount of progress has been 
made in  understanding the mechanisms of toxicity  of some drugs,  particularly 
those  that  induce  liver  injury  in  a  predictable  fashion.  The  liver  metabolizes 
virtually every drug or toxin introduced in the body (Roberts 2001). The majority 
of drug induced liver toxicity is happened during the cytochromes P450 catalyzed 
metabolism  of  drug  in  liver  (Zuber  et  al.  2002).  Oxidative  stress  plays  an 
important role on xenobiotic-induced hepatotoxicity and cell death. Many drugs 
lead to the production of free radicals which cause severe oxidative stress in liver 
along with decrease levels of antioxidant liver enzymes, leading liver cell damage. 
Manifestations of drug induced liver toxicity are pigment accumulation, hepatic 
fibrosis and cirrhosis, acute cholestasis, chronic cholestasis, autoimmune hepatitis, 
vascular lesions/venoocclusive disease and neoplastic lesions. 
OXIDATIVE STRESS
Oxidative Stress  (OS) is a general term used to describe the steady state 
level of oxidative damage in a cell, tissue, or organ, caused by the reactive oxygen 
species (ROS). OS is caused by an imbalance between the production of reactive 
oxygen and  a  biological  system's  ability  to  readily  detoxify  the  reactive 
intermediates  or  easily  repair  the  resulting  damage  (Sikka  et  al.  1995).  Under 
normal  conditions,  ROS are cleared  from the cell  by the  action  of  superoxide 
dismutase (SOD), catalase (CAT), or glutathione peroxidase (GPx) (Agarwal and 
Prabakaran 2005). The main damage to cells on oxidative stress results from the 
ROS-induced alteration of macromolecules such as polyunsaturated fatty acids in 
membrane lipids, essential proteins, and DNA. Additionally, oxidative stress and 
ROS  have  been  implicated  in  disease  states,  such  as  Alzheimer's  disease, 
Parkinson's  disease,  cancer,  aging  and  pathogenesis  of  various  liver  diseases 
including  alcoholic  liver  disease,  nonalcoholic  fatty  liver  disease,  and chronic 
hepatitis  C (Roskams et  al.,  2003;  Seki  et  al.,  2003;  Blanchetot and  Boonstra 
2008). 
Reactive Oxygen Species (ROS) and Free Radicals
Reactive oxygen species (ROS) include a number of chemically reactive 
molecules derived from oxygen (Fridovich 1999) and free radicals are atoms or 
groups of atoms with an odd (unpaired) number of electrons and can be formed 
when  oxygen  interacts  with  certain  molecules  (Halliwell  1999).  Most  of  the 
reactive  oxygen  species  in  the  body  are  free  radical  (except  like  hydrogen 
peroxide).  They  participate  in  several  physiological  functions,  and  form  an 
integral part of the organism’s defense against invading microbial agents (Babior 
2000).  They are known mediators of intracellular signaling cascades (Scandalios 
2002; Klein and Ackerman 2003).  They accelerate aging and contribute to the 
development of many diseases, including cardiovascular, neurosensory disorders, 
inflammation, cancer (Reddy and Clark 2004; Saha and Channon 2004; Waris and 
Ahsan 2006). 
Most free radicals come from the endogenous sources as by-products of 
normal  and  essential  metabolic  reactions,  such  as  energy  generation  from 
mitochondria or the detoxification reactions involving the liver cytochrome P-450 
enzyme  system  (Nohl  et  al.  2003).  Exogenous  sources  include  exposure  to 
cigarette smoke, environmental pollutants such as emission from automobiles and 
industries,  consumption  of  alcohol  in  excess,  asbestos,  exposure  to  ionizing 
radiation, and bacterial, fungal or viral infections. 
Figure 2: Formation of Free Radical
 It can cause tissue damage by reacting with lipids in cellular membranes, 
nucleotides in DNA (Ahsan et al.  2003), sulfhydryl  groups in proteins (Knight 
1995)  and  cross-linking/fragmentation  of  ribonucleoproteins  (Waris  and  Alam 
1998). 
Superoxide radical (O2.-)
Superoxide is the anion O2−.. Superoxide is biologically quite toxic and is 
deployed by the immune system to kill invading microorganisms. In phagocytes, 
superoxide is produced in large quantities by the enzyme NADPH oxidase for use 
in  oxygen-dependent  killing  mechanisms  of  invading  pathogens  (Lotz  2003). 
Superoxide  is  also  deleteriously  produced  as  a  byproduct  of  mitochondrial 
respiration as  well  as  several  other  enzymes,  for  example  xanthine  oxidase 
(Kuppusamy and Zweier 1989).
The biological toxicity of superoxide is due to its capacity to inactivate 
iron-sulfur  cluster containing  enzymes  (which are critical  in  a wide variety of 
metabolic  pathways),  thereby  liberating  free  iron  in  the  cell  and  generate  the 
highly  reactive  hydroxyl radical.   In  its  HO2 form  (hydroperoxyl  radical), 
superoxide can also initiate lipid peroxidation of polyunsaturated fatty acids. 
Hydrogen peroxide (H2O2)
Among  different  activated  oxygen  species,  H2O2,  which  is  not  a  free 
radical,  has  a  relatively  longer  half-life  and  may  play  a  significant  role  in 
oxidative stress injury. Different oxidases enzymes, especially xanthine oxidase, 
monoamine  oxidase,  and NADH oxidase  produce  H2O2,  which  directly  and/or 
indirectly through the production of highly reactive hydroxyl radicals can cause 
tissue injury. It plays a radical forming role as an intermediate in the production of 
more reactive ROS molecules including HOCl (hypochlorous acid)  by the action 
of  myeloperoxidase,  an  enzyme  present  in  the  phagosomes  of  neutrophils 
(Winterbourn et al. 2000) and, most importantly, formation of •OH  via oxidation 
of transition metals.
H+ + Cl-   + H2O2   → 3 HOCl + H2O
Hydroxyl Radical (.OH)
Due to its strong reactivity with biomolecules, •OH is probably capable of 
doing more damage to biological systems than any other ROS (Betteridge 2000; 
Halliwell 1987). It is mainly produce from H2O2 in the presence of Cu2+/Fe3+. This 
reaction is called Fenton reaction (Aruoma et al. 1989):
H2O2 + Cu+/Fe+ →   •OH + OH- + Cu2+/Fe3+ 
 Figure 3: Major ROS pathway and antioxidant defenses    
 Reactive Nitrogen Species:
Nitric oxide represents an odd member of the free radical family and is 
similar  to  O2•-  in  several  aspects  in  that  it  does  not  readily  react  with  most 
biomolecules despite its unpaired electron. NO is synthesized enzymatically from 
L-arginine by NO synthase (NOS) (Andrew 1999).
     
                          L-arginine + O2 + NADPH → L-citrulline + NO + NADP+ 
If O2.- is produced in large amounts in parallel with NO, the two react with each 
other  to give OONO- (peroxynitrite),  which is  highly cytotoxic  (Hughes 2008; 
Beckman  and  Koppenol  1996).  Peroxynitrite  may  react  directly  with  diverse 
biomolecules in one- or two-electron reactions,  readily react with CO2 to form 
highly  reactive  nitroso  peroxocarboxylate  (ONOOCO2-),  or  protonated  as 
peroxonitrous acid (ONOOH) undergo homolysis to form either •OH and •NO2 or 
rearrange to nitrate (NO3).
Singlet oxygen (1O2)
Singlet oxygen is described as an important ROS in reactions related to 
ultraviolet  exposition  (UVA,  320-400  nm).  During  the  degradation  of  lipid 
peroxides  the  singlet  O2 is  generated  (Miyamoto  et  al.  2007).  Its  toxicity  is 
reinforced when appropriate photo excitable compounds (sensitizers) are present 
with molecular oxygen. Diets rich of metals contributes to increase the production 
of singlet oxygen. 
Lipid peroxidation 
Lipid peroxidation, mediated by free radicals, involves the direct oxidative 
reaction  of  oxygen  and  lipids  to  form  radical  intermediates  and  semistable 
peroxides. Cell membranes are phospholipid bilayers with extrinsic proteins and 
are the direct target of lipid peroxidation. 
Figure 4: Overview of lipid peroxidation. Abbreviations: NRP, nonradical 
product; LOOH, lipid hydroperoxide; -TOH, -tocopherol; -TO·, -TOH 
radical; LH, lipid substrate; LOO·, lipid peroxyl radical. 
Oxidation of lipids in biological systems proceeds via a chain reaction consisting 
of  three phases:  initiation,  propagation,  and termination  (Waldeck and Stocker 
1996).
• Initiation: This phase of lipid peroxidation may proceed by the reaction of 
an activated oxygen species such as singlet oxygen (1O2), ·O2-, or HO· with 
a lipid substrate or by the breakdown of preexisting lipid hydroperoxides 
by transition metals and generate a highly reactive carbon-centered lipid 
radical (L·).
• Propagation:  This  phase  of  lipid  peroxidation,  molecular  oxygen  adds 
rapidly to  L· at  a  diffusion controlled  rate  to  produce the lipid  peroxyl 
Propagation:  This  phase  of  lipid  peroxidation,  molecular  oxygen  adds 
rapidly to  L· at  a  diffusion controlled  rate  to  produce the lipid  peroxyl 
radical (LOO·). The peroxyl radical can abstract a hydrogen atom from a 
number of in vivo sources, such as DNA and proteins, to form the primary 
oxidation product, a lipid hydroperoxide (LOOH).
• Termination  of  lipid  peroxidation  occurs  via  the  coupling  of  any  two 
radicals to form nonradical products. Nonradical products are stable and 
unable to propagate lipid peroxidation chains.
Oxidized lipids can affect cell  function by accumulating in the cell membrane, 
causing  leakage  of  the  plasmolemma  and  interfering  with  the  function  of 
membrane-bound receptors (Cai and Harrison 2000).
ANTIOXIDANT 
To prevent damage to cellular components, there are numerous enzymatic 
antioxidant defenses designed to scavenge ROS in the cell. Oxidation reactions in 
the  body  produce  ROS  which  produce  oxidative  stress  and  cell  damage. 
Antioxidants  terminate  oxidative  damage  by  scavenging  free  radical 
intermediates, and inhibit other oxidation reactions by being oxidized themselves. 
Hence,  antioxidants  are  said  to  be  “free  radical  scavengers”;  their  roles  are 
unavoidably suicidal. As oxidative  stress  might  be an important  part  of  many 
human diseases, the use of antioxidants in  pharmacology is intensively studied, 
particularly as treatments for liver disease, stroke and neurodegenerative diseases. 
For that diet rich in antioxidant prevent the oxidative damage of cell. Fruits and 
vegetables are rich source of antioxidant. Studies shows that people who consume 
a diet rich in fruits and vegetables have a lower risk of cancer, liver injury, heart 
disease and other oxidative stress related disease.
Antioxidant Enzymes
Antioxidants can fit into two broad categories_ enzymatic and non-enzymatic. 
They provide the necessary defense against the OS generated by ROS. Different 
classes of antioxidants that scavenge ROS:
• Enzymatic antioxidant
                    Superoxide dismutase (SOD)
                    Catalase (CAT)
                    Glutathione peroxidase/Glutathione reductase (Gpx/GR)
Non-enzymatic antioxidants
                     Vitamins C, Vitamin E, Vitamin A
                     Proteins like Albumin, Transferrin, Heptoglobulin
                          Gluthathion (GSH)
Superoxide dismutase
The first  enzyme  involved in  the antioxidant  defense is  the  superoxide 
dismutase: a metalloprotein found in both prokaryotic and eukaryotic cells. SOD 
can be divided into various classes according to the catalytic metal present at the 
active site. SOD1 (CuZnSOD) is found in the cytosol and contains copper (Cu) 
and zinc (Zn) as metal cofactors (Marklund 1982). SOD2 (MnSOD) is present in 
mitochondria  and  contains  Mn.  SOD3  (ECSOD)  is  present  extraceullarly 
(Weisiger and Fridovich 1973). Of these, Cu/Zn-SOD and Mn-SOD are the main 
forms. The biosynthesis of SOD is mainly controlled by its substrate, the O2–.. 
2O2 +2H+ H2O2 + O2
SOD
SOD  scavenges  both  intracellular  and  extracellular  superoxide  radical  and 
prevents  the  lipid  peroxidation  of  plasma  membrane.  However,  it  should 
conjugate with catalase or GPx to prevent the action of H2O2, which promotes the 
formation  of  hydroxyl  radicals  (Jeulin  et  al.  1989).  SOD  also  prevents 
hyperactivation and capacitation induced by superoxide radicals (Lamirande and 
Gagnon 1995). 
Catalase
Catalase  present  in  almost  all  the  mammalian  cells  is  localized  in  the 
peroxisomes or the microperoxisomes.  It  is  a  hemoprotein  and detoxifies  both 
intracellular  and  extracellular  hydrogen  peroxide  to  water  and  oxygen  (Mates 
2000) thus protects the cell from oxidative damage by H2O2 and .OH. In addition, 
catalase activates NO. induced sperm capacitation, which is a complex mechanism 
involving  H2O2 (Lamirande  1997).  Catalase  activity  has  been  detected  in 
hepatocytes.
2H2O2 H2O + 1/2O2
Catalase
Figure 5: Antioxidant Enzymes System 
Glutathione peroxidase/reductase system (GPx/GR)
Importance of the GPx/GR system is centered on its antilipoperoxidative 
defense in human cell. GPx reacts with peroxides and requires reduced glutathione 
(GSH) as the reductive substance donating an electron (Mates et al. 1999). It is a 
seleno-enzyme; two-third of which (in liver) is present in the cytosol and one-third 
in  the  mitochondria  (Ursini  et  al.  1995).  The  first,  isozyme  GPx1,  prevents 
apoptosis  induced by OS. The second and the third isozymes are found in the 
gastrointestinal tract and in plasma, respectively. The fourth form acts directly on 
membrane phospholipid hydroperoxides and detoxifies them (Dreher et al. 1997). 
GR stimulates the reduction of GSSG to GSH (Rana et al. 2002). 
2GSH + R(OOH)COOH GSSG + R(OH)COOH + H2O
GPX
GSSG    +    NADPH   +   H+ GSH   +   NADP+
GR
Glutathione
Gluthione  (GSH),  a  tripeptide  consisting  of  L-γ-glutamyl-L-
cysteinylglycine,  is  the  most  abundant  intracellular  thiol  compound  present  in 
virtually all mammalian tissue (Irvine 1996; Sen 1997). It is a peptide composed 
of glutamate, cysteine and glycine that exist in thiol-reduced glutathione (GSH) 
and oxidized glutathione (GSSG) (Meister and Anderson 1983). 
Role of GSH:
• It  plays  a  vital  role  in  annihilating  oxygen  toxicity  by interrupting  the 
reaction leading to O2-. formation. 
• The multiple physiological and metabolic functions of GSH include thiol 
transfer reactions that protect cell membranes and proteins. 
• GSH  participates  in  reactions  that  destroy  hydrogen  peroxide,  organic 
peroxides, free radicals and certain foreign compounds. 
• GSH participates by number of chemical mechanisms in the metabolism of 
various endogenous compounds. 
• GSH functions in the transport of amino acids.
• GSH also serves to detoxify compounds either via conjugation reactions 
catalyzed  by glutathione  S-  transferase  or  directly,  as  is  the  case  with 
hydrogen peroxide in the GPx catalyzed reaction. 
Glutathione  plays  a  key  role  in  the  liver  in  detoxification  reactions  and  in 
regulating the thio-sulphide status of the cell.  The liver  is  very active in GSH 
biosynthesis  and  translocates  GSH to  the  blood  plasma.  GSH is  essential  for 
maintaining the reducing capacity of cells, the loss of this capacity may cause the 
cell  to  die.  This  mechanism  of  cell  death  is  mediated  by  mitochondrial 
dysfunction  caused  due  to  the  absence  of  a  minimum  concentration  of  GSH 
required by mitochondria which also affects the ATP production in cells. 
IMMUNOSUPPRESSANT DRUGS
Immunosuppressant  drugs  are  medicines  that  reduce  the  body's  natural 
defenses against  foreign invaders or materials.  These drugs are mainly used in 
transplant patients to prevent the rejection of transplanted organs. When an organ, 
such as a liver, a heart or a kidney, is transplanted from one person (the donor) 
into another (the recipient), the recipient's immune system has the same response 
it  has  to  any  foreign  material.  It  attacks  and  tries  to  destroy  the  organ. 
Immunosuppressant  drugs  help  prevent  this  from  happening  by  subduing the 
natural immune response. In addition to being used to prevent organ rejection, 
immunosuppressant drugs sometimes are used to treat severe skin disorders such 
as  psoriasis  and  other  diseases  such  as  rheumatoid  arthritis,  Crohn's  disease 
(chronic inflammation of the digestive tract) and patchy hair loss (alopecia areata) 
and various autoimmuno diseases.
According to specific mode of action the Immunosuppressant drugs can be 
classified. Among various immunosuppressant drugs, now a day in organ 
transplantation mainly three drugs are used: 
• Azathioprine:  Disrupt the synthesis of DNA and RNA and cell division. 
• Cyclosporine:  Act by inhibiting T-cell activation, thus preventing T-cells 
from attacking the transplanted organ. 
• Corticosteroids such as prednisolone: These drugs suppress the 
inflammation associated with transplant rejection.
Most  patients  are  prescribed a  combination  of  immunosuppressant  drugs  after 
their  transplant,  one  from  each  of  the  above  main  groups;  for  example 
cyclosporine, azathioprine and prednisolone. Over a period of time, the doses of 
each drug and the number of drugs taken may be reduced as the risks of rejection 
decrease. However, most patients need to take at least one immunosuppressive for 
the rest of their lives. But these drugs are very powerful and can cause serious side 
effects,  such  as  high  blood  pressure,  kidney  problems  and  liver  problems. 
Immunosuppressant drugs lower a person's resistance to infection and can make 
infections harder to treat. Other side effects loss of appetite, nausea or vomiting, 
increased hair growth, and trembling or shaking of the hands. 
Azathioprine
Azathioprine (AZA) a synthetic purine analogue has been extensively used 
as  used  as  an  immunosuppressive  agent  and  indicated  as  an  adjunct  for  the 
prevention of rejection in organ transplantation like renal,  cardiac,  hepatic  and 
pancreatic transplantations (Opelz 1995; Kunz and Neumayer  1997). AZA also 
used in various diseases, like inflammatory bowel disease (Vernier-Massouille et 
al. 2007), rheumatoid arthritis (Whisnant and Pelkey 1984), autoimmuno hepatitis 
(Heneghan and McFarlane 2002), systemic lupus erythematosus (Abu-Shakra and 
Shenfeld 2001) and Crohn’s disease (CD) (Kaskas et al. 2003). In spite of its wide 
range  of  clinical  uses, AZA  leads  to  serious  adverse  drug  reaction  such  as 
hepatotoxicity,  hepatobiliary  carcinomas,  pancreatitis,  gastrointestinal 
disturbances and bone marrow suppression (Sterneck et al. 1991; Connell et al. 
1993). 
Figure 6: Structure of Azathioprine (6-(1-Methyl-4-nitroimidazol-5-ylthio) purine)
Physico-chemical Properties:
                     Relative molecular mass: 277.3
                     Molecular formula: C9H7N7O2S   
                     Melting point: 244° C        
                     Colour       :     Pale yellow. 
      State/form:      Powder. 
                     Description:     Odourless
Insoluble in water and very slightly soluble in ethanol.
Figure 7: Metabolism of Azathioprine
          Azathioprine (AZA) undergoes a rapid nonenzymatic conversion in the 
yielding 6-mercaptopurine(6-MP). During this process GSH is consumed. 6-MP is 
metabolized  by three  enzymes  (xanthine  oxidase,  thiopurine  methyltransferase 
(TPMT)  and  hypoxanthine  phosphoribosyl  transferase).  Xanthine  oxidase  and 
TPMT  catalyse  the  reaction  of  6-MP  to  6-thiouric  acid  (6-TU)  and  6-
methylmercaptopurine  (6-MMP),  respectively.  The  TPMT  enzyme  system  is 
responsible  for the formation  of 6-thioinosine-monophosphate  (6-TIMP) which 
may  ultimately  be  transformed  into  the  pharmacologically  active  6-
thioguaninenucleotides: 6-thioguanine-monophosphate (6-TGMP), 6-thioguanine-
diphosphate (6-TGDP) and 6-thioguanine-triphosphate (6-TGTP).
Azathioprine mode of action: 
The exact mechanism of immunosuppressive activity of azathioprine has 
not been determined. AZA primary metabolite 6-MP is readily converted by the 
enzyme  HPRT  and  TPMT  into  a  number  of  active  purine  thionucleotide 
metabolites. These purine metabolites act to inhibit purine synthesis. Azathioprine 
which  is  an  antagonist  to  purine  metabolism  may  inhibit  RNA  and  DNA 
synthesis.  The  drug  may  be  incorporated  into  nucleic  acids  resulting  in 
chromosome  breaks,  malfunctioning  of  the  nucleic  acids.  The  drug  may  also 
inhibit  coenzyme  formation  and  functioning,  thereby  interfering  with  cellular 
metabolism. Mitosis may be inhibited by the drug. These nucleotide-dependent 
processes  provide  azathioprine  with  both  immunosuppressive  and  cytotoxic 
properties. 
FLAVONOIDS
Flavonoids comprise a large group of polyphenolic compounds which are 
present in high concentration in certain vegetables (onions), fruits (apples, grapes 
etc), seeds, beverages (tea and wine) as secondary metabolites (Middleton et al. 
2000; Heim et al. 2002). Flavonoids have been reported for many salutary effects 
on  human  health  including  anti-inflammatory  (Kim  et  al.  2004),  antiallergic 
(Kawai et al. 2007), cardioprotective (Hertog et al. 1993) and anticancer activity 
(Kuo  1997).  In  addition,  it  shows  protective  effect  against  DNA  damage  in 
oxidative stress condition (Bonnesen et al. 2001; Webster et al. 1996).  It has been 
stated that their broad pharmacological activities are mainly attributed due to their 
antioxidant  properties  (Korkina  and  Afanas’ev  1997).  Flavonoids  exhibit 
antioxidant properties by scavenging free radicals (Afanas’eve et al. 1989; Bors et 
al.  1990) and in this  fashion protect  cellular  components  against  the oxidative 
stress.  Hence,  diets  rich  in  flavonoids  reduce  the  risk  of  chronic  liver  injury 
associated with oxidative stress.  The capacity of flavonoids to act as antioxidants 
depends upon their molecular structure. The position of hydroxyl groups and other 
features in the chemical structure of flavonoids are important for their antioxidant 
and free radical scavenging activities. 
Quercetin
 Quercetin belongs to the flavonoids family and consists of 3 rings and 5 
hydroxyl  groups.  Quercetin  is  also  a  building  block  for  other  flavonoids.  QE 
occurs in food as an aglycone (attached to a sugar molecule). QE is found in many 
common foods including apple, tea, onion, nuts, berries, cauliflower and cabbage 
(Morand et al. 1998; Hollman et al. 1997). 
Figure 8: Structure of Quercetin (3, 5, 7, 3’, 4’–pentahydroxyflavone)
Physico-chemical Properties:
                     Relative molecular mass: 302.24
                     Molecular formula: C15H10O7   
                     Melting point: 310°C_317°C       
                     Colour       :     Yellow. 
      State/form:      Crystalline Powder. 
                     Description:     Odourless
                     Stability: Stable under ordinary conditions. Moisture sensitive.
Practically insoluble in water and very slightly soluble in ethanol and propylene 
glycol.
Quercetin has many health promoting effects, including improvement of 
cardiovascular disease (Duarte et al. 2001). QE inhibits the type of inflammation 
that can occur in the joints of those with arthritis. Quercetin has anti-inflammatory 
and anti-allergic effects  (Formica and Regelsonw 1995).  All these activities are 
caused by the strong antioxidant action of quercetin. It will help to combat free 
radicals molecules, which can damage cells. As many other flavonoids, quercetin 
prevents the oxidation of LDL (bad) cholesterol. The anti-inflammatory action of 
quercetin is caused by the inhibition of enzymes, such as lipoxygenase, and the 
inhibition  of  inflammatory  mediators.  Quercetin  also  inhibits  the  release  of 
histamine,  which causes congestion,  by basophils  and mast  cells.  Studies have 
shown that quercetin reduces the cancer risk of prostate, ovary, breast, gastric and 
colon cells  (Yoshida et al. 1990).  QE may play a role in the prevention and/or 
treatment of eye disorders by neutralizing free radicals.  Quercetin also seems to 
reduce the production of uric acid,  by inhibiting the xanthine oxidase,  thereby 
easing  gout  symptoms.  Studies  have  shown  an  improved  liver  function,  lung 
function and lower risk of certain respiratory diseases (asthma and bronchitis) for 
people with high diet of fruits and vegetable (rich in quercetin) intake.
REVIEW OF LITERATURE
Ferrali et  al.  1997; have  studied  the  protective  effect  of  flavonoid  QE 
against oxidative damage of erythrocyte membrane. They have incubated 
GSH  depleted  mouse  erythrocytes  with  the  oxidants  phenylhydrazine, 
acrolein,  divicine  and  isouramil  which  resulted  in  increase  lipid 
peroxidation  and  hemolysis.  But  with  the  addition  of  the  flavonoid  QE 
resulted in remarkable protection against lipid peroxidation and hemolysis.
Inal and Kahraman 2000; have demonstrated the protective effect of QE on UV 
mediated  oxidative  stress  in  rats.  In  their  study,  malondialdehyde  (MDA), 
reduced glutathione (GSH), glutathione reductase (GSSGR), glutathione 
peroxidase (GPx), catalase (CAT) and superoxide dismutase (SOD) levels 
were measured in the liver of rats exposed to UVA light in various doses. 
The  effects  of  quercetin  were  determined  as  antioxidant  on  those 
parameters.  Rats  were  divided  into  three  groups  as  control,  ultraviolet 
(UV), and ultraviolet+quercetin (UV+QE). UV and UV+QE group rats were 
irradiated 4 h perday with UVA light (1.25 mW/cm2) during periods of 0, 3, 
6,  9  days.  Quercetin  (50  mg/kg  body  wt.)  was  administered 
intraperitoneally  before each irradiation period in  the UV+Q group rats. 
The level of MDA was increased and other antioxidant enzymes activity  
were significantly decrease on-6 and 9th day on UV exposed rats. But in 
their study they have shown that the MDA level  of was decreased and 
antioxidant  enzyme level  of  UV+QE groups were  significantly increase. 
From  their  study  it  has  proved  the  usefulness  of  QE  on  reducing  or 
preventing photobiologic damage.
Peres et al. 2000;  have done a research on amelioration of liver damage in rats 
with  biliary  obstruction  by  flavonoid  QE.  In  their  study  bile  duct  obstruction 
resulted in a  decrease in the activities  of antioxidant  enzymes,  reduce ratio  of 
liver  oxidized/reduced  (GSSG/GSH)  glutathione  ratio,  increase  hepatic  and 
mitochondrial  thiobarbituric  acid  reactive  substances  (TBARS)  and  collagen 
content and a marked fibrosis and bile ductular proliferation. But treatment with 
quercetin increase the glutathione level and other antioxidant enzymes level. Their 
results  suggest  that  QE might  be  a  useful  agent  to  preserve  liver  function  in 
patients with biliary obstruction.
Alice and Geoffrey 2001; reviewed mechanism of Azathioprine induced injury to 
hepatocytes:  they  stated  that  roles  of  glutathione  depletion  and  mitochondrial 
injury  Azathioprine  causes  cell  death  through  reduced  glutathione (GSH) 
depletion and mitochondrial injury. Toxicity to rat hepatocytes was preceded by 
depletion  of  GSH.  In  hepatocytes,  Glutathione  (GSH)  is  consumed  during 
metabolism of azathioprine to 6-mercaptopurine. 6-Mercaptopurine was not toxic 
to hepatocytes, suggesting that the later steps in  Azathioprine  metabolism were 
not  related  to  the  pathogenic  mechanism.  Ultra  structural  studies  showed 
hepatocyte mitochondrial lesions after exposure to  Azathioprine,  but no features 
of apoptosis. Azathioprine produced rapid and profound depletion of adenosine 5'-
triphosphate (ATP). 
 
Chitra et al.  2001;  have proved the protective effect  of QE on AZA induced 
membrane change in the mouse spleen. In their study AZA treatment caused an 
increase  in  serum  albumin/globulin  ratio,  membrane  bound  ATP-ase  and  a 
decrease in total protein in spleen tissue. Treatment with QE decreased activities 
of membrane ATP-ase and serum albumin/globulin ratio and it also increased the 
total protein in serum. So their studies support the protective role of QE against 
the AZA induced toxicity on spleen.
 
Hanan et al. 2001; have done synergistic salubrious effect of QE, coenzyme Q10 
(CoQ10) on lipid peroxidation and nitric oxide generation in endotoxin-induced 
shock  in  rat  brain.  They  induced  shock  by  i.p.  injection  of  10  mg/kg-1 of 
lipopolysaccharide (LPS) and were biochemically manifested 2 h after injection as 
an  increase  in  brain  malondialdehyde  (MDA),  total  nitrite/nitrate  (NOx), 
glutathione  peroxidase  (GSHPx),  and  blood  lactate  level/activity.  Pretreatment 
with quercetin 2 h before LPS injection diminished the shock-induced increases in 
brain MDA, and NOx levels while elevating the reduced brain phospholipids’ and 
serum SH groups’ content. Their studies shows that QE and CoQ10 ameliorate the 
oxidative status of brain during the early phase of endotoxic shock.
Molina et  al.  2003;  have proved the effectiveness of  quercetin  against 
ethanol induced oxidative stress by directly quenching lipid peroxides and 
indirectly  by  enhancing  the  production  of  the  endogenous  antioxidant 
GSH.  In  their  study  a  significant  increase  in  lipid  peroxidation 
(malondialdehyde,  MDA)  products  was  observed  in  liver  tissue  after 
administration  of  ethanol  and  the  antioxidants  enzymes  levels  were 
decrease in ethanol administered animals. But pre- and post- treatment 
with  QE  significantly  increased  the  level  of  antioxidant  enzymes  and 
attenuated the MDA level. According to their results, they have suggested that 
pretreatment  with  QE  is  more  effective  than  post  treatment  against  ethanol 
induced oxidative stress. 
Raza et al., 2003: have done research work on a comparison of hepatoprotective 
activities of amino guanidine and  N-acetylcysteine in rat against  AZA induced 
hepatotoxicity. They suggested AZA is an important drug used in the therapy of 
autoimmune system disorders. It induces hepatotoxicity that restricts its use. The 
rationale behind their study was the proven efficacy of  N-acetylcysteine (NAC) 
and  reports  on  the  antioxidant  potential  of  amino  guanidine  (AG;  an  iNOS 
inhibitor), that might be useful to protect against the toxic implications of AZA. 
This pretreatment  also resulted in a significant  decline in the contents  of lipid 
peroxides  and  a  significant  elevation  in  GSH  level  was  evident  after  AZA 
treatment.  These  observations  also  indicate  that  the  improvement  in  the  GSH 
levels by NAC is the most significant protective mechanism rather than any other 
mechanistic profile.  
Guzy  et  al.  2004;  have  reviewed  that  antioxidant  effect  QE on  paracetamol-
induced rat liver mitochondrial dysfunction. In their study they investigated the 
effect of paracetamol and QE on mitochondrial oxygen consumption, activities of 
mitochondrial enzymes like ATP-ase, GR, GPx. Pretreatment with QE prevent the 
increase  activity  of  ATP-ase  on  paracetamol  administration  and  increase  the 
enzymic activity of GR and GPx. These results indicated the usefulness of QE to 
mitigate paracetamol-induced liver mitochondria dysfunction. 
Janbaz et al. 2004;  have reviewed that possible protective effect  of QE and 
caffeic  acid  against  paracetamol  and  CCL4-induced  hepatic  damage.  They 
suggested that QE and caffeic acid were able to prevent paracetamol and CCL4-
induced rise in the serum marker enzymes (AST and ALT) and also prevented the 
CCL4-induced prolongation in pentobarbital sleeping time which confirmed their 
hepatoprotectivity.  From  their  result  they  have  concluded  caffeic  acid  and 
quercetin  exhibited  hepatoprotective  activity  possibly  through  multiple 
mechanisms.
Singh et  al.  2004; have  investigated  the  protective  effect  of  QE  on 
ischemia/reperfusion induced renal injury in rats. They have shown pretreatment 
of animals with quercetin (2 mg/kg and 30 mg/kg, i.p.) markedly attenuated renal 
dysfunction,  morphological  alterations,  reduced  elevated  TBARS  levels  and 
restored the depleted renal antioxidant enzymes as compare to I/R induced rats, 
whereas  the  (100 mg/kg,  p.o.)  dose  of  quercetin  failed  to  revert  the  renal  I/R 
induced changes. From their finding they implied that ROS play a causal role 
in I/R induced renal injury and quercetin exerts protective and deleterious 
effects in the kidney, depending upon the dose.
Amin  and  Hamza  2005;  have  proved  the protective  effect  of  Hibiscus, 
Rosmarinus and  Salvia  against AZA induced liver toxicity.  In their  study they 
have observed the elevated level of marker enzymes like AST, ALT along with 
MDA on AZA treated group. In their study the level of antioxidant enzymes were 
also decreased on AZA administration.  But pretreatment  with any of the three 
herbal plants used in their investigation proved to have a protective effect against 
AZA-induced hepatotoxicity by decreasing elevated marker enzymes, MDA level 
and increasing the antioxidant enzyme level.
Coskun et al. 2005; have conducted the studies on modulation of streptozotocin 
(STZ)-induced  oxidative  stress  and  β-cell  damage  in  rat  pancreas  by  the 
flavonoids  QE.  They  have  proved  the  protective  effect  of  QE  against  STZ–
induced  diabetic  rats,  possibly  through  decreasing  lipid  peroxidation,  NO 
production  and  increasing  antioxidant  enzyme  activity.  Apart  from these  they 
have  observed  increased  immunohistochemical  staining  of  insulin  and 
preservation of islet cells were apparent in the QE-treated diabetic rats as compare 
to  STZ  induced  diabetic  rats.  From  their  study  it  has  been  proved  that  QE 
treatment  has  protective  effect  in  diabetes  by  decreasing  oxidative  stress  and 
preservation of pancreatic β-cell integrity.
Tokyol et al. 2006;  have done synergistic salubrious effect of  Desferrioxamine 
and QE against ischaemia-reperfusion induced liver damage in rats. In their study 
tissue MDA levels and Plasma alanine aminotransferase activity were increase, 
but  treatment  with  Desferrioxamine  and  Quercetin  significantly  decrease  the 
MDA level and decrease the ALT activity as compare to ischaemia/reperfusion 
rats. Their data suggest that both desferrioxamine and QE may be useful to protect 
against ischaemia-reperfusion induced liver damage.
 
AIM AND SCOPE
 Organ transplantation is displacing of a whole or partial  organ from one 
body to another (or from a donor site on the patient's own body), for the purpose 
of replacing the recipient's damaged or failing organ with a working one from the 
donor  site.  Organ  transplants  can  be  categorized  as  "life-saving",  but  organ 
transplanted  patient  need  life  long  immunosuppressive  therapy. Azathioprine, 
imidazole  derivative  of  6-mercaptopurine  (6-MP),  is  an  one  of  the  important 
immunosuppressive  drug  which  is  mainly  used  for  the  prevention  of  graft 
rejection in organ transplantation (Opelz 1995; Kunz and Neumayer 1997) as well 
as in autoimmune diseases, like inflammatory bowel disease, rheumatoid arthritis, 
systemic lupus erythematosus (Abu-Shakra and Shenfeld 2001). AZA has gained 
a  prominent  place  as  an  immunosuppressive  maintenance  therapy for  Crohn’s 
disease (CD) (Kaskas et al. 2003). In spite of its wide range of clinical uses, AZA 
leads  to  serious pathological  consequences  such as hepatotoxicity,  pancreatitis, 
gastrointestinal disturbances and bone marrow suppression (Sterneck et al. 1991; 
Connell  et  al.  1993).  It  has  been  well  documented  that  hepatotoxicity  is  an 
important complication in the course  of AZA therapy (Elsing et al. 2007) which 
includes, nodular regenerative hyperplasia, veno-occlusive disease (Daniel et al. 
2005; Russmann et al. 2001).                                       
Mounting  studies  suggest  that  hepatotoxicity  of  AZA  is  due  to  the 
depletion of glutathione (GSH) (Alice and Geoffrey 2001) during metabolism of 
AZA to 6-mercaptopurine (6-MP) (Clamers et al. 1969). Depletion of GSH leads 
to generation of ROS that subsequently trigger mitochondrial  swelling and cell 
necrosis, thereby culminating in cell death (Raza et al. 2003). With the decline in 
endogenous GSH level, lipid peroxidation in hepatocytes is increased which leads 
to  oxidative  injury.  Thus,  oxidative  stress  plays  a  pivotal  role  in  the 
aetiopathogenesis  of  AZA induced  hepatotoxicity.  In  several  literatures,  it  has 
been cited that oxidative stress causes pronounced decrease in cellular antioxidant 
levels (Vijayakumar et al. 2006; Ghosh and Sil 2007) In this line, AZA which is 
known  to  impose  oxidative  stress  on  hepatic  tissue  hampers  the  enzymatic 
antioxidants’  activities  in  liver  leading  to  potential  liver  damage  (Amin  and 
Hamza 2005). Hence, antioxidant supplementation might protect liver from AZA-
induced hepatotoxicity by augmenting the cellular antioxidant levels.                 
Quercetin (3, 5, 7, 3’, 4’–pentahydroxyflavone) is a safe, common and one 
of the most abundant flavonoid. Literature data suggest the protective potential of 
QE against oxidative stress (Morel et al. 1993). Earlier studies evidence that QE 
could be used as an anti-ulcer (Martin et al. 1993), anti-allergic, anti-inflammatory 
(Formica  and  Regelsonw  1995),  anticancer  (Yoshida  et  al.  1990)  and 
antihypertensive  (Duarte  et  al.  2001).  Moreover,  it  has  been  reported  for  its 
potential  protective  effect  on  carbon  tetrachloride,  ethanol  and  paracetamol 
induced hepatotoxicity (Janbaza et al. 2004; Molina et al. 2003). Several lines of 
evidence indicate that QE elevates the levels of antioxidant enzymes and prevents 
in vitro and in vivo lipid peroxidation in oxidative stress conditions (Coskun et al. 
2005; Ferry et al. 1996; Fiorani et al. 2001).  
Interestingly,  a  previous  report  showed  that  quercetin  has  a  protective 
effect on azathioprine induced membrane change in the mouse spleen (Chitra et 
al. 2001). In the light of the above findings, the present study was embarked upon 
to  evaluate  the  protective  effect  of  QE against  AZA-elicited  oxidative  hepatic 
damage in rats.  
PLAN OF WORK
Evaluation of protective effect of flavonoid quercetin against azathioprine 
induced  oxidative  liver  injury  in  male  Wistar  rats  by  estimation  of  following 
parameters. 
In vivo study
1.      Estimation of Marker Enzymes in serum.
• AST
• ALT
• ALP
• GGT
• LDH
2.       Estimation of Total Bilirubin in serum.
 3. Estimation of MDA levels in liver tissue. 
4.      Estimation of Antioxidant Enzymes in Liver Tissue.
  
• SOD
• CAT
• GPx
• GR
• GSH
5.      Estimation of Total Protein in liver tissue.
6.      Estimation of Nuclic Acids in Liver
          
• DNA
• RNA
   7.  Histopathological study of liver. 
MATERIALS AND METHODS
Animal model
This  study  was  conducted  using  male  albino  Wistar  rats  (150±10  g). 
Animals were obtained from the Animal House, Vel’s College of Pharmacy, The 
Tamilnadu  Dr.  M.G.R.  Medical  University,  Chennai,  India.  Animals  were  fed 
with commercially available standard rat pelleted feed from M/s Hindustan Lever 
Limited,  Bangalore,  India.  The feed  and water  were provided  ad libitum.  The 
animals were deprived of food for 24 h before experimentation but allowed free 
access  to  tap  water  throughout.  The  rats  were  housed  under  conditions  of 
controlled temperature (25±2 ◦C) and were acclimatized to 12-h light: 12-h dark 
cycles.  Experimental  animals  were  used  after  obtaining  prior  permission  and 
handled  according  to  the  Institutional  Animal  Ethical  Committee  (IAEC)  of 
Committee  for  the  Purpose  of  Control  and  Supervision  of  Experiments  on 
Animals (CPCSEA), Ministry of Social Justice and Empowerment, Government 
of India.
Experimental protocol
 The experiment was carried out for 7 days. The experimental animals were 
randomized into four groups of six rats each as follows:
 Group  I: Control  rats,  administered  intraperitoneally  with  normal  saline 
         (1mL/kg  Body weight) for 7 days.
Group II: Rats, administered with single intraperitoneal injection of AZA (50 
mg/kg body weight, suspended in saline) on 7th day.        
Group III: Rats, administered with intraperitoneal injection of QE (50 mg/kg 
body weight, suspended in saline) for 7 days. 
Group IV: Rats were pretreated with QE suspension (50 mg/kg body weight, 
suspended in saline, i.p.) for 7 days; then on the 7th day, 1 hr after 
administration of QE the rats were given a single intraperitoneal  
injection of AZA as Group II. 
At  the  end  of  experimental  period  (8th day),  all  the  animals  were 
anesthetized by diethyl ether and sacrificed by cervical decapitation. Blood was 
collected immediately and the sera were separated by centrifugation at 10,000 rpm 
for  10  min,  the  separated  serum samples  were  used  for  marker  enzymes  and 
bilirubin  estimation.  The liver  was immediately dissected  out  and liver  tissues 
were immediately excised and rinsed in ice cold physiological  saline and then 
liver tissue was homogenized in Tris-HCl buffer (0.1M, pH 7.4). Then the liver 
tissue homogenate  was centrifuged and supernatant  was collected.  Supernatant 
tissue  (liver)  homogenate  were  instantly  processed  and  used  for  estimation  of 
MDA, antioxidants, nuclic acids (DNA and RNA) and total protein. 
BIOCHEMICAL ESTIMATIONS
1. Liver Marker Enzymes:
a. Estimation of Aspartate aminotransferase (AST, E.C.2.6.1.1)
The enzyme activity was assayed by the method of Reitman and Frankel 
(1957).
     Reagent
1. Phosphate buffer: 0.1M, pH 7.4
2. Substrate:  Dissolved 2.66 g of D-aspartic  acid and 38 mg of α- 
ketoglutaric acid in 20.0 mL 0.1N sodium hydroxide with gentle 
heating. This was made up to 100 mL water.
3. 2,  4-dinitrophenyl  hydrazine  (DNPH)  reagent:  1.0  mM 
dinitrophenyl hydragine in 2.N hydrochloric acid. 
4. Sodium hydroxide: 0.4N.
5. Standard pyruvic acid: 10 mg of sodium pyruvate was dissolved in 
10 ml of phosphate buffer 0.1M, pH 7.4
Procedure
In different tubes, 1.0 mL the buffered substrate was added to 0.1 mL of 
serum and incubated at 37o C for one hour. Then 1.0 mL of DNPH reagent was 
added to arrest the reaction. To the blank tubes, 0.1mL of enzyme was added only 
after the addition of DNPH reagent. The tubes were kept aside for 15 minutes, and 
then 10 mL of 0.4N Sodium hydroxide was added and read at 520 nm in a UV 
spectrophotometer.
 The enzyme activity is expressed as IU L-1 of serum. 
b. Estimation of Alanine aminotransferase (ALT, E.C.2.6.1.2)
The reagents and methods used were the same as those used for the assay 
of AST (Reitman and Frankel 1957) but substrate solution was different and the 
incubation time was reduced to 30 minutes.
Substrate
78  g  of  DL-  alanine  and  38  mg  of  α-Ketoglutarate  were  dissolved  in 
buffer. 0.5 ml of sodium hydroxide was added and the volume was made up to 
100 mL with buffer.
The enzyme activiry was expressed as IU L-1 of serum.
c. Estimation of Alkaline Phosphatase (ALP, E.C.3.1.3.1)
Alkaline phosphatase was assayed by the method of Kind and King (1954) 
using disodium phenyl phosphate as the substrate.
      Reagents
1. Carbonate-bicarbonate buffer-0.1M, pH10.0 
2. Substrate: 0.01M disodium phenyl phosphate solution 
3. Folin’s phenol reagent 
4. Sodium carbonate 
5. Magnesium chloride 0.1M. 
6. Standard  phenol  solution:  A  solution  of  distilled  crystalline  phenol  in 
water containing 5.0µg in 0.1mL was prepared. 
Procedure
  The  incubation  mixture  contained  the  following  compounds  in  a  final 
volume of 3.0 mL of carbonate-bicarbonate buffer: 1.0 mL of substrate and 0.1mL 
magnesium  chloride  and  requisite  amount  of  the  enzyme  source  (0.2mL  of 
serum). The reaction mixture was incubated at 37o C for 15 minutes. The reaction 
was terminated  by the  addition  of  1.0 mL Folin’s  phenol  reagent.  If  turbidity 
appeared, the tubes were centrifuged. Controls without enzyme source were also 
incubated and the enzyme source was added after the addition of Folin’s phenol 
reagent.  Then  1.0  mL  of  1  5%  sodium  carbonate  solution  was  added  and 
incubated further for 10 minutes at 37o  C. the blue color developed was read at 
640nm against blank. The standard was also reared similarly. 
The activity if the enzyme is expressed as IU L-1 of serum.           
d. Estimation of Gamma Glutamyl Transpeptidase (GGT, E.C.2.3.2.2)
The activity of gamma glutamyl transpeptidase (GGT) in serum was 
assayed by the procedure of Gabor (1969).
Reagent
1. Ammediol-(2-arnino-2-m ethyl-propane-1, 3-diol) -HC1 buffer, 0.05 M,  
 pH 8.6  
2. Substrate was prepared by dissolving L-γ-Glutamyl-p-nitroanilide,   
             glycylglycine and magnesium chloride in the buffer solution (solution 1).
Procedure
0.1 mL of serum was taken in each of six microcuvets and then 1 mL. 
buffered substrate was added by using micropipette with continuous stirrerring in 
the electric stirrer. The increase in absorbance was measured at 403 nm at 25ºC. 
For each test the increase in absorbance was noted every 1 min. for 5 min., and 
average per minute is calculated.
The activity if the enzyme is expressed as IU L-1 of serum. 
d. Assay of Lactate Dehydrogenase (LDH, E.C.1.1.1.27)
Lactate dehydrogenases was assayed according to the method of King (1965)
Reagents:
1. 0.1M glycine buffers: 7.5 g of glycine and 5.85 mg of sodium chloride 
were dissolved in one litre of distilled water.    
2. Buffed substrate: 2.76 g of lithium lactate was dissolved in 1.0 ml of 
distilled water just before use.
3. 0.4 N NAOH.
4. 5.0 mg of NAD+ was dissolved in 1.0 ml of distilled water just before use.
5. 2, 4- dinitrophenyl hydrazine reagent (DNPH): 200 mg of DNPH was 
dissolved in one litre of 1 N HCl.
6. Standard pyruvate solution: 12.5 mg of sodium pyruvate was dissolved in 
100 ml of buffer. 
Procedure:
To 1.0 mL of the buffered substrate, 0.1 mL of enzyme preparation was 
added and the tubes were incubated at 370C for 15 min. After adding 0.2 mL of 
NAD+ solution, the incubation was continued for another 15 min. The reaction 
was  then  arrested  by  adding  1.0  mL  of  DNPH  reagent  and  the  tubes  were 
incubated for a further period of 15 min at 370C after which 7.0 mL of 0.4 N 
sodium hydroxide was added and the colour developed was measured at 420 nm 
in a Shimadzu UV spectrophotometer. Suitable aliquots of the standards were also 
analyzed by the same procedure.
              The activity of the enzyme was expressed as IU L-1 in serum and moles of 
pyruvate liberated/mg protein in tissue.
2. Estimation of Total bilirubin 
     Estimation of total bilirubin was estimated according to method of D Amour 
FF (1965). Methods of detecting and estimating bilirubin in serum are based on 
the formation of red or purple compound, azobilirubin, when bilirubin reacts with 
Diazo reagents introduced by Van Den Bergh.
      The reaction consists of two parts – the direct and the indirect reaction. The 
latter serves as a quantitative estimation of serum billirubin. 
Principle
   Diazo reagents  react  with bilirubin in  acidic  condition to  give a red or 
purple complex which can be measured quantitatively at 530 nm or yellow light. 
Diazo reagent is added to serum if the bilirubin is present; a red or purple colour 
appears due to azobilirubin. This called direct Van Den Bergh reaction. In this 
case three different responses can be seen. 
a. A prompt direct reaction which reaches completion of reaction in 30 sec. 
b. The delayed direct  reaction  in which,  the colour  only begins to  appear 
from 5-30 mins. After mixing the serum and diazo reagent. 
c. No direct reaction may be observed. 
Free bilirubin does not react with the diazo reagent unless a coupling agent is 
added  –  ethyl  or  methyl  alcohol  is  generally  is  after  this  addition  the  whole 
bilirubin  is  converted  into  the  azobilirubin.  This  stage  is  known  as  indirect 
reaction. 
Reagent 
1. Diazo reagent- was prepared freshly before use by adding solution (B) into 
10mL solution (A) 
Solution (A): 1 gm of sulphanilic acid was dissolved in 15 mL of conc. HCl and 
the Vol was made up to 1 L with water.
Solution (B): 0.5 gm of sodium nitrate was dissolved in water and the volume 
was made up to 100 mL in water. 
For use 10mL of diazo A is mixed with 0.3mL of diazo B. The solution was 
freshly prepared in frequent intervals. 
2. Diazo Blank- 15 mL Conc HCL was mixed with distilled water and 
the volume was made up to 1L.
Techniques 
Fresh serum, 2 mL., was pipetted in each of the two test tubes. To of one 
tube 0.5 mL diazo reagent was added (test) and to the another tube 0.5 mL diazo 
blank was added (blank). Then kept for 15 min and after that tubes are mixed with 
5.7 mL of distilled water and 70% alcohol and kept for 10 mins. The reading was 
taken at 540 nm. 
 The level of total bilirubin was expressed as mg dL-1 of serum.
3. Estimation of malondialdehyde (MDA)
In  the  liver  tissue  samples,  lipid  peroxidation  (in  terms  of  MDA) was 
determined by the method of Ohkawa et al. (1979).
Reagents
1. 8·1% sodium dodecyl sulphate
2. 20% acetic acid
3. 0·8% aqueous solution of thiobarbituric acid (TBA)       
4. 1 Ν NaOH
5.  Mixture of n-butanol and pyridine (15:1)
Procedure 
The reaction mixture contained 0·1 mL of tissue homogenate, 0·2 mL of 
8·1% sodium dodecyl sulphate (SDS), 1·5 mL of 20% acetic acid and 1·5 mL of 
0·8% aqueous solution of thiobarbituric acid (TBA). The pH was adjusted with 1 
Ν NaOH to 3·5. The mixture was finally made up to 4·0 mL with distilled water  
and heated at 95°C for 60 min on an oil bath. After cooling under tap water, 1·0 
mL of distilled water and 5·0 mL of a mixture of n-butanol and pyridine (15:1) 
was  added  and  the  mixture  was  shaken  vigorously  on  a  vortex  mixer.  After 
centrifugation at 2200 rpm for 5 min the absorbance of the organic layer (upper 
layer) was measured immediately at 532 nm.
 The activity was expressed as µmole mg-1protein. 
4. Assay of Antioxidant Enzymes 
a. Assay of Superoxide Dismutase (SOD) 
SOD was assayed by the method of Marklund and Marklund (1997). 
Reagents
1. Tris HCL buffer 0.1 M, pH 8.2
2. Tris HCL buffer 0.05 M, pH 7.9
3. Pyrogallol stock solution, 2mM in 0.05 M Tris HCL buffer
Procedure
            The assay mixture for the enzyme contained 2 mL of 0.1 M Tris HCL 
buffer 0.5 mL of pyrogallol, 0.5 mL of aliquots of the enzyme extract and water to 
give a final volume of 4 mL. The rate of inhibition of pyrogallol auto-oxidation 
after the addition of the enzyme was noted at 470 nm at on interval of one minute 
for minutes.
      The enzyme activity was expressed in units min-1 mg -1 protein.
b. Assay of Glutathione peroxidase (GPx)
Glutathione peroxidase (GPx) was assayed by the method of Rotruck et al. 
(1973).
Reagents
1. 0.4 M Tris–HCl buffer, pH 7.0
2. 10 mM sodium azide
3. Reduced glutathione
4. 0.2 mM hydrogen peroxide
5. Ellman’s reagent
6. Sodium nitrate
Procedure
 Reaction mixture contained 0.2 mL of 0.4 M Tris–HCl buffer, pH 7.0, 0.1 
mL of 10 mM sodium azide, 0.2 mL of tissue homogenate (homogenized in 0.4 M 
Tris–HCl buffer, pH 7.0), 0.2 mL glutathione and 0.1 mL of 0.2 mM hydrogen 
peroxide.  The  contents  were  incubated  at  37ºC for  10  min.  The reaction  was 
stopped by 0.4 mL of 10% TCA, and centrifuged. Supernatant was assayed for 
glutathione  content  by using Ellman’s  reagent  (19.8 mg of 5,  5’-dithiobisnitro 
benzoic acid in 100 mL of 0.1% sodium nitrate). . Final GSH content in reaction 
mixture  was determined by Ellman’s  reagent  and absorbance was measured at 
410-412 nm.
The enzyme activity was expressed as µmole of GSH oxidized min-1mg-1 
protein.
c. Assay of Catalase (CAT)
Catalase activity was assayed by the method of Sinha (1972). 
Reagent
1. Potassium dichromate
2. Glacial Acetic Acid
3. Phosphate Buffer (pH 7.4)
4. Hydrogen peroxide
Procedure
The tissue homogenate (0.5 mL) was added to the reaction mixture containing 
1mL of 0.01 M phosphate buffer (pH 7.0), 0.5 mL of 0.2 M H2O2, 0.4 mL H2O 
and  incubated  for  different  time  period.  The  reaction  was  terminated  by  the 
addition  of  2  mL of  acid  reagent  (dichromate/acetic  acid  mixture)  which  was 
prepared by mixing 5% potassium dichromate  with glacial  acetic  acid (1:3 by 
volume). To the control, the enzyme was added after the addition of acid reagent. 
All the tubes were heated for 10 minutes and the absorbance was read at 610 nm. 
CAT activity was expressed in terms of µ-moles of H2O2 consumed min-1mg-1 
protein.
d. Assay of Glutathione reductase (GR):
Glutathione reductase (GR) was assayed by the method of Smith et al. 
(1988). 
Reagents
1. 5, 5’-dithiobis (2-nitrobenzoic acid)
2. NADPH
Procedure
GR activity was measured by monitoring the rate of production of 5-thio-
2-nitrobenzoic acid (TNB) from 5, 5’-dithiobis (2-nitrobenzoic acid) (DTNB) at 
412  nm,  which  is  coupled  with  the  GR  reaction.  Homogenates  (5%)  were 
centrifuged for 10 min at 8400 rpm; assays were performed on crude supernatants 
as  described,  except  that  no  glutathione  disulfide  was  added  to  the  reaction 
mixture. The blank with no NADPH in the mixture was subtracted from the rate 
with  0.1  mM  NADPH  (final  concentration)  for  each  sample.  Activity  was 
calculated  based on the change in  absorbance  at  412nm for  2.0–4.8 min  after 
simultaneous mixing of control and experimental samples and blanks.
The enzyme activity was expressed as nmole TNB formed mg-1protein 
min-1.
e. Determination of Total Reduced Glutathione (GSH):
Total reduced glutathione (GSH) was determined by the method of Ellman 
et al. (1959). 
Reagent
1. 5, 5’-dithio-bis-(2nitrobenzoic acid)
2. 2-nitro-5-mercaptobenzoic acid
3. 10% trichloroacetic acid
4. 6 mM disodium ethylene diamine tetra acetic acid
5.  0.1M potassium phosphate buffer (pH 8)
Procedure
In  the  liver  homogenate,  reduced  glutathione  (GSH)  activity  was 
determined  based  on  the  reduction  of  Ellman’s  reagent  [5,  5’-dithio-bis-
(2nitrobenzoic acid)] by SH groups to form 1mole of 2-nitro-5-mercaptobenzoic 
acid  per  mole  of  SH (Ellman,  1959).  The  nitro-mercaptobenzoic  acid  has  an 
intense yellow color and can be determined spectrophotmetrically. To 0.5 mL of 
10% trichloroacetic acid, 6 mM disodium ethylene diamine tetra acetic acid, 0.5 
mL of homogenate was added and shaken gently for 10-15 minutes.  This was 
followed by centrifugation at 2000 rpm for 5 minutes. 0.2 mL of the supernatant 
was mixed with 1.7 mL of 0.1M potassium phosphate buffer (pH 8). At least a 
duplicate was made for each sample. 0.1 mL of Ellman’s reagent was added to 
each tube. After 5 minutes, the optical density was measured at 412 nm against a 
reagent blank. 
The activity was expressed as µmole g-1tissue. 
5. Estimation of Total Protein:                           
The total protein content in liver was estimated according to the Lowry’s 
method (1951).
Reagent 
1. Alkaline copper reagent                            
         Solution A: 2% sodium carbonate in 0.1 N NaOH.
Solution B: 0.5% copper sulfate in 1% sodium potassium tartarate. 50 ml of 
solution A was mixed with 1 ml of solution B just before use.
2. Folin’s phenol reagent (commercial reagent, 1:2 dilutions). 
Procedure: 
                 
 To 0.1 mL of suitably diluted homogenate, 0.9 mL of water and 4.5 ml of 
alkaline copper  reagent  were added and kept at  room temperature for 10 min. 
Then 0.5 ml of Folin’s reagent was added and the colour developed was read after 
20 min at 640 nm.
      The protein level expressed as mg 100mg-1 of protein. 
6. Estimation of Nucleic acids
The  method  described  by  Bregman  (1983) was  used  to  determine  the 
levels of nucleic acids.
Reagent
1. Trichloroacetic acid (TCA)
2. Diphenylamine
3. Orcinol
Procedure 
The liver was homogenized and the homogenate was suspended in ice-cold 
trichloroacetic  acid  (TCA).  After  centrifugation,  the  pellet  was extracted  with 
ethanol. The levels of DNA were determined by treating the nucleic acid extract 
with diphenylamine reagent and reading the intensity of blue color at 600 nm. For 
quantification of RNA, the nucleic acid extract was treated with orcinol and the 
green color was read at 660 nm.
      The nucleic acids were expressed as μg 100mg-1.
HISTOPATHOLOGICAL STUDIES
The experiment lasted in 24 hours and the animals were sacrificed by ether 
anesthesia. Liver from each rat was stored in 10% neutral formalin solution. Three 
lobes  of  each  rat  liver  were  processed  and  sectioned.  By  following  routine 
histological  techniques,  these  samples  were  put  into  paraffin  and  serial  cross 
sections of 5 micrometers,  which were taken from tissue blocks.  For each rat, 
three slides were made and stained with hematoxylin and eosin. The preparations 
were evaluated under a photomicroscope and were photographed (Olympus BH-
2).
STATISTICAL ANALYSIS
The results  were expressed as mean ± standard deviation (S.D.) for six 
animals  in each group. Differences between groups were assessed by one-way 
analysis  of  variance  (ANOVA)  using  the  SPSS  13.0  software  package  for 
Windows. Post hoc testing was performed for inter-group comparisons using the 
least significance difference (LSD) test; p-values < 0.05 have been considered as 
statistically significant.
 
RESULTS
Effect of Quercetin on Diagnostic Liver Marker Enzymes:  
In the present study, intraperitoneal administration of a single dose of AZA 
(50 mg/kg body weight) induced severe biochemical changes as well as oxidative 
damage  in  liver.  After  24  hours  of  AZA  treatment,  a significant  (p  <  0.05) 
increase in the levels of diagnostic liver marker enzymes (AST, ALT, ALP, LDH 
and GGT) and total bilirubin were observed in the serum of AZA administered 
(Group II) rats as compared to that of Group I control rats  (Table 1,2 and Fig. 
9,10,11,12,13,14).  In contrast, pretreatment of Group IV animals with quercetin 
(50 mg/kg body weight) significantly (p < 0.05) decreased the elevated levels of 
marker enzymes and total bilirubin to near normalcy as compared to Group II. In 
quercetin alone treated rats (Group III) versus controls (Group I), no significant 
difference was observed.
Effect of Quercetin on lipid peroxidation in Liver:
Table 4 and figure 20 show the levels of the MDA in the liver of control 
and experimental group of rats. MDA levels were found to be markedly elevated 
(p < 0.05) in AZA administrated rats (Group II) when compared to control rats 
(Group I). This elevated level of hepatic MDA was completely reversed to near 
normalcy on pretreatment with QE (Group IV) and non-significant variation was 
observed in QE alone treated rats (Group III) when compared to control (Group 1) 
Role of Quercetin on Antioxidant status in liver tissue:              
Tables  3  and  Figures  (15,  16,  17  and18)  represent  the  activities  of 
enzymatic antioxidants (SOD, CAT, GPx, and GR). Table 4 and Figure 19 show 
the levels of the non enzymatic antioxidant (GSH) in liver tissue of control and 
experimental groups. Significant (p < 0.05) reduction in the antioxidant status was 
observed in  rats  induced with AZA (Group II)  when compared to control  rats 
(Group I). In the present study these adverse changes were significantly (p < 0.05) 
reversed to near normalcy and an improvement in antioxidant status was noticed 
in  rats  pretreated  with  QE (Group IV).  However,  rats,  treated  with  QE alone 
(Group  III)  did  not  show  any  significant  changes  when  compared  to  control 
(Group I). 
Effect of QE on proteins and nucleic acids in liver
AZA supplementation induced significant (p < 0.05) decrease in liver total 
protein,  nuclic acids (DNA and RNA) concentration as compare to the control 
groups of  rats  (Group II).  Pretreatment  with QE (Group IV) shows protection 
against  decrease levels of total  protein nuclic  acids (DNA and RNA) by AZA 
administration (Table 5 and Fig. 21, 22). In quercetin alone treated rats (Group III) 
versus controls (Group I), no significant difference was observed.
Histopathological Studies:
The hepatocytes in AZP-treated rats displayed clear cellular degeneration 
and  loss  of  the  distinct  liver  characteristic  configuration  which  include 
inflammatory cell infiltration, focal necrosis and sinusoidal dilation (Fig. 24). 
Pre-treatment  with QE prevented the Histopathological  changes  in  rats  (Group 
IV). The liver appears normal except for a few scattered degenerated cells  (Fig. 
26). Control rat and QE alone treated rat liver showing normal architecture of liver 
cells (Fig. 23 and 25).
DISCUSSION
Azathioprine, an extensively used immunosuppressant shows complicacy 
in  the  course  of  therapy  due  to  its  various  adverse  reactions.  Among  these, 
hepatotoxicity  is  an  important  complication  which  involves  the  syndrome  of 
vascular liver damage (Katzka et al.  1986; Sterneck et  al.  1991). The possible 
sources of liver injury in AZA therapy have been reported in animal models and in 
patients.  Amin  and  Hamza  (2005)  reported  that  liver  injury  in  AZA-induced 
oxidative stress is mediated by the inhibition of the antioxidant enzymes thereby 
enhancing the production of the free radicals which lead to lipid peroxidation and 
hepatocellular  cellular  damage.  Previous  studies showed that  the agents  which 
exhibit antioxidant, free radical scavenging properties show protective effect on 
reactive oxygen species (ROS) mediated oxidative stress in liver (Borges et al. 
2008; Senthilkumar et al. 2006). In the present study, we examined the protective 
effect of the antioxidant quercetin in AZA induced liver injury.     
Liver injury due to AZA intoxication could be assessed by measuring the 
serum liver marker enzymes which are the biochemical hallmarks of hepatic tissue 
damage  (Raza  et  al.  2003).  The  transaminase  enzymes,  such  as  aspartate 
transaminase  (AST) and alanine  transaminase  (ALT) are regarded as the most 
reliable  markers  of  hepatic  injury  (Chenoweth  and  Hake  1962).  Alkaline 
phosphatase (ALP) is a membrane-bound enzyme and its alteration is likely to 
affect the membrane permeability as well as transportation of metabolites (Ahmed 
et  al.  1999).  Lactate  dehydrogenase  (LDH),  an  intracellular  enzyme,  whose 
increase in serum is also a crucial diagnostic marker of liver necrosis (Kim et al.  
2001). Gamma glutamyl  transpeptidase (GGT), located on the outer surface of 
plasma membrane, plays an important role in antioxidant defense system and its 
concentration in serum is the early marker of cell  damage and oxidative stress 
(Lee and Jacobs 2005).  Any damage to the hepatic tissue leads to the release of 
these enzymes into the circulation, thereby showing increased serum levels with a 
concomitant  decline  in  the  liver  (Sallie  et  al.  1991).  Several  lines  of  studies 
showed that QE possesses the property to decrease the levels of marker enzymes 
in oxidative insults (Janbaza et al. 2004). In this present study, the increased levels 
of these enzymes and bilirubin in serum after 24 hours of AZA treatment reflect 
the annihilating effect  of AZA on the cell  membrane,  ensuing in  an increased 
release  of  functional  enzymes  from intracellular  locations,  which confirms  the 
hepatotoxic  effect  of  AZA. Administration  of  QE  significantly  alleviated  the 
levels of hepatic marker enzymes and total bilirubin in the serum of AZA-exposed 
rats, which infers that the AZA-induced alterations in hepatocellular membrane 
might have been protected through membrane stabilization effect of QE.  
AZA-induced liver damage is associated with increased lipid peroxidation 
(Amin and Hamza 2005). Lipid peroxidation, mediated by free radicals, involves 
the  direct  reaction  of  oxygen  and  lipids  to  form  radical  intermediates  and 
semistable  peroxides.  Cell  membranes  are  phospholipid  bilayers  with extrinsic 
proteins and are the direct target of lipid peroxidation which leads to a number of 
deleterious  effects  such as  increased  membrane  rigidity,  osmotic  fragility,  cell 
membrane destruction and cell damage (Thampi et al. 1991). Lipid peroxidation is 
thought  to  be  an  important  mechanism  of  liver  injury  and  malondialdehyde 
(MDA)  is  one  of  its  end  products,  which  is  generated  during  the  oxidative 
degradation of lipids (Leibovitz and Siegel 1980). Hence, measurement of MDA 
can be used to assess lipid peroxidation in liver. In this study, AZA treated rats 
depicted  increased  level  of  MDA,  which  is  a  reflection  of  enhanced  lipid 
peroxidation leading to liver tissue damage and failure of antioxidant enzymes in 
prevention of excess ROS. On the contrary, it has been observed that the MDA 
levels in the QE treated rats were significantly decreased when compared to the 
AZA rats. These results corroborate well with the previous reports which showed 
that QE can prevent lipid peroxidation by directly scavenging free radicals  and 
quenching the lipid peroxidative chain (Coskun et al. 2005; Hanan et al. 2001). 
Based  on  this  scenario,  reduction  in  the  level  of  MDA  was  due  to  the 
antiperoxidative effect of quercetin.  
Previous studies demonstrated that the primary route for AZA toxicity is 
depletion of glutathione (Alice and Geoffrey 2001). Gluthione (GSH), a tripeptide 
consisting of L-γ-glutamyl-L-cysteinylglycine, is the most abundant intracellular 
thiol present in virtually all  mammalian tissues (Irvine 1996; Sen 1997)  and it 
protects  the  tissues  against  in  vivo toxicity  of  sulfhydryl  binding  toxicants 
(Naganuma  et  al.  1990).  This  cysteine  containing  tripeptide  prevails  either  in 
reduced (GSH) or oxidized (GSSG) form and regulates the thiol status of the cell. 
In liver it plays a key role in detoxification reactions and protects the liver against 
ROS such as peroxy radical, super oxide radical, and alkoxy radical by both non-
enzymatic as well as enzymatic mechanisms, as GSH acts as a substrate  for the 
H2O2 removing  enzyme,  glutathione  peroxidase  (Puglia  and  Powell  1984). 
Excessive decline in the level of GSH not only make the cells more vulnerable to 
ROS, but also hampers the basic cellular functions drastically (Uhlig and Wendel 
1992). In this study extensive reduction in GSH level observed in AZA treated 
rats, might be due to the consumption of GSH during the metabolism of AZA to 
6-mercaptopurine  (6-MP)  which  produce  severe  oxidative  stress  and  lipid 
peroxidation in liver. It has been stated that the quercetin plays an important role 
in improving the GSH status (Singh et al. 2004; Inal and Kahraman 2000),  by 
incrementing the production of GSH (reduced glutathione) from GSSG (oxidized 
glutathione), via induction of the enzyme GR, which  explains the elevation of 
GSH activity that in turn stimulates GPx activity (Molina et al. 2003). In he present 
study, pretreatment with QE replenished the hepatic GSH level which mitigates 
oxidative liver damage, in AZA treated rats.  
The enzymic antioxidant defense system includes mainly SOD, CAT, GPx 
and GR and this system protect cells against O2 toxicity and lipid peroxidation. 
SOD  converts  the  superoxide  anion  radical  to  hydrogen  peroxide,  and  CAT 
cleaves this hydrogen peroxide into the molecules of water and oxygen (Mates 
2000). GPx is a selenoenzyme that catalyses the oxidation of GSH to GSSG and 
there by scavenges the H2O2 and simultaneously GR catalyzes the reduction of 
GSSG to GSH (Rana et al. 2002). In the present study the SOD, CAT, GPx and 
GR enzymes’ levels were decreased in AZA treated group. The decreased activity 
of GPx in the AZA administered rats is due to the fact that AZA depletes the GSH 
which  is  the  substrate  for  GPx.  Due  to  this  diminished  activity  of  GPx, 
accumulation  of  H2O2 takes  place,  leading  to  inhibition  of  other  antioxidant 
enzymes  (Sinet  and Garba  1981).  This  phenomenon  consequently  leads  to  an 
increase  in  the  steady  state  of  oxidants  and  severe  oxidative  stress  with 
accumulation  of  free  radicals  in  liver.  According  to  the  previous  reports,  QE 
scavenges superoxide and hydroxyl radicals and prevent the formation of peroxy 
radicals (Robak and Gryglewski 1998; Husain et al. 1987). Evidences indicated 
that the free radical scavenging action of QE may be due to the presence of  3-
hydroxyl group in C-ring and 3', 4’-dihydroxy groups in the B-ring (Kim et al. 
2006; Rice-Evans et al. 1997). In agreement with the previous reports (Singh et al. 
2004; Inal and Kahraman 2000), in this study the liver antioxidant levels of SOD, 
CAT, GPx and GR were increased in QE pretreated rats exposed to AZA, which 
might be due to anti-radical/antioxidant effect of QE.
In present study, hepatic nucleic acids (DNA & RNA) and total protein 
levels depleted significantly in AZA treated rats. Pretreatment with QE showed 
significant  protection  against  decreased  hepatic  nucleic  acids  levels  by  AZA 
administrations. Several studies reported that, toxic agents such as chemotherapy 
drugs, carcinogens, reactive oxygen and nitrogen species cause damage in DNA 
and  RNA  molecules  (Bohr  2002;  Kang  and  Hamasaki  2005).  It  is  well 
documented that flavonoids quercetin  is an efficient  radical scavenger,  activate 
enzymes important for detoxification and prevent in vivo DNA damage and lipid 
peroxidation (Muthukumaran et al. 2008). The present result indeed support such 
notion  because  QE supplementation  could  effectively  increased  AZA induced 
decrease in DNA, RNA and total protein concentration in liver.  
Histopathological  investigations  of  the  liver  also  provided  supporting 
evidence for this work. Rats pretreated with QE showed reduced damage in liver 
after  24  hours  of  AZA administration.  From this,  it  is  evident  that  quercetin 
possesses  the  protective  activity  against  azathioprine  induce  liver  toxicity.  In 
conclusion, from this study it is evident that QE possess the capability to 
alleviate the AZA-induced oxidative damage in liver, which could be due to 
its  antioxidant nature,  which  includes  free  radical  scavenging  and cell 
membranes stabilizing properties.
SUMMARY & CONCLUSION
In  the  present  study,  quercetin  was  taken  up  for  extensive  studies  to 
evaluate  the  hepatoprotective  potential  against  azathioprine  induced  oxidative 
liver  injury  in  male  Wistar  rats.  Liver  injury  was  induced  in  rats  by  single 
intraperitoneal  injection  of  AZA  (50  mg/kg  body  weight).  It  was  found  that 
pretreatment  with  QE for  7  days  at  a  dosage  50  mg/kg  body weight  through 
intraperitoneal route was able to reverse most of the deleterious effects in liver 
induced by AZA.
The outcome of this study was summarized below.
    In this study, the increased levels of marker enzymes and bilirubin in 
serum after  24 hours of  AZA treatment  were observed.  Administration  of QE 
significantly alleviated the levels of hepatic marker enzymes and bilirubin in the 
serum of  AZA-exposed rats,  which  infers  that  the  AZA-induced alterations  in 
hepatocellular  membrane  might  have  been  protected  through  membrane 
stabilization effect of QE.  
An enhancement in lipid peroxidation with a simultaneous depression in 
the levels of non-enzymatic antioxidant GSH was observed in Wistar rats treated 
with AZA. QE pretreatment significantly decreased lipid peroxidation and elevate 
the GSH on AZA exposed rats which reflect the antiperoxidative and antioxidant 
effect of QE.
            In the present study the SOD, CAT, GPx and GR enzymes’ levels were  
decreased in AZA treated group. But  the liver antioxidant levels of SOD, CAT, 
GPx and GR were increased in QE pretreated rats exposed to AZA, which might 
be due to its free radical scavenging activity of QE.
Hepatic nucleic acids (DNA and RNA) and total protein levels depleted 
significantly in AZA treated rats mainly due to the oxidative damage of hepatic 
tissue.  Pretreatment  with  QE  showed  significant  protection  against  decreased 
hepatic nucleic acids levels and protein by AZA administration.
The  results  of  functional  tests,  together  with  histological 
observations, suggest that AZA accumulation leads to serious changes in 
the  histology  of  the  liver,  including  inflammatory  cell  infiltration,  focal 
necrosis  and  sinusoidal  dilation,  thus  imposing  a  health  risk.  AZA 
decreases the GSH level and disturbs the redox state of the cells . The 
increased  formation  of  lipid  peroxides  and  associated  reactive  oxygen 
species leads to a collapse in membrane integrity and other pathological 
changes in the liver. The antioxidant nature and free radical scavenging 
activity of QE which would be helpful in protecting the structural integrity of 
cells,  thus, emphasizing the efficacy of QE in reducing the pathological 
changes and  caused by AZA in liver tissue. In addition, the contribution of 
QE  to  improving  the  antioxidant  defense  could  be  responsible  for  the 
preservation  of  liver  architecture  and  functions,  as  indicated  by 
normalization of hepatic markers in AZA administered to QE-treated rats.
  In conclusion, this study suggests that QE possess the capability 
to alleviate the AZA-induced oxidative damage in liver, which could be due 
to its antioxidant nature, which includes free radical scavenging and cell 
membranes stabilizing properties. 
Table 1: Effect of azathioprine and quercetin on the activities of liver marker
          enzymes AST, ALT and ALP in serum of control and experimental rats
Groups             AST
(IU L-1)           
ALT
(IU L-1)
       
ALP
(IU L1)
Group I
(Control) 59.23 ± 2.61 40.45 ± 1.15 22.96 ± 1.37
Group II
(AZA) 126.82 ± 7.81a,* 79.04 ± 3.42a,* 52.81 ± 3.02a,*
Group III
(QE) 59.91 ± 2.27NS 39.17 ± 1.73NS 20.83 ± 0.84NS
Group IV
(AZA+QE) 68.55 ± 2.70b,*
  
45.43 ± 2.02b,* 27.7 ± 1.27b,*
Results are expressed as mean ± S.D. for 6 rats. Comparisons are made between: a-Group 
I and Group II; b-Group II and Group IV.    * Statistically significant (p < 0.05); NS – 
non-significant
Table 2: Effect of azathioprine and quercetin on the activities of liver marker
enzymes LDH, GGT and Bilirubin in serum of control and experimental rats
Groups LDH
(IU L-1)
GGT
(IU L-1)
Bilirubin
(mg dL-1)
Group I
(Control) 387.87 ± 14.56 3.00 ± 0.13 0.41 ±0.03
Group II
(AZA) 567.53 ± 34.85a,* 9.05 ± 0.48a,* 1.55 ± 0.07 a,*
Group III
(QE) 390.07 ± 9.96NS 3.14 ± 0.12NS 0.46 ± 0.03 NS
Group IV
(AZA+QE) 412.50 ± 16.75b,* 3.82 ± 0.23b,* 0.96 ± 0.05 b,*
 Results are expressed as mean ± S.D. for 6 rats.  Comparisons are made between: a-
Group I and Group II; b-Group II and Group IV.    * Statistically significant (p < 0.05); 
NS – non-significant
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Fig. 9: Levels of AST in the serum of the experimental animals and expressed as IU L -1. 
Results are given as mean ± S.D. for six rats.  Comparisons are made between: a-Group I 
and Group II;  b-Group II and Group IV.   * Statistically significant (p < 0.05); NS – non-
significant.
0
10
20
30
40
50
60
70
80
90
Control AZA QE AZA+QE
IU
 L
-1
ALT
a,*
b,*
NS
Fig. 10: Levels of ALT in the serum of the experimental animals and expressed as IU L -1. 
Results are given as mean ± S.D. for six rats. Comparisons are made between: a-Group I 
and Group II;   b-Group II and Group IV.   * Statistically significant (p  < 0.05); NS – 
non-significant.
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Fig. 11: Levels of ALP in the serum of the experimental animals and expressed as IU L -1. 
Results are given as mean ± S.D. for six rats. Comparisons are made between: a-Group I 
and Group II;   b-Group II and Group IV.   * Statistically significant (p  < 0.05); NS – 
non-significant. 
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Fig. 12: Levels of LDH in the serum of the experimental animals and expressed as IU L-1. 
Results are given as mean ± S.D. for six rats. Comparisons are made between: a-Group I 
and Group II;   b-Group II and Group IV.   * Statistically significant (p  < 0.05); NS – 
non-significant. 
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Fig. 13: Levels of GGT in the serum of the experimental animals and expressed as IU L-1. 
Results are given as mean ± S.D. for six rats. Comparisons are made between: a-Group I 
and Group II;   b-Group II and Group IV.   * Statistically significant (p  < 0.05); NS – 
non-significant. 
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Fig. 14: Levels of Bilirubin in the serum of the experimental animals and expressed as 
mg dL-1. Results are given as mean ± S.D. for six rats. Comparisons are made between:  
a-Group I and Group II;   b-Group II and Group IV.   * Statistically significant (p < 0.05); 
NS – non-significant.
Table 3: Effect of Azathioprine and Quercetin on the activities of enzymic
antioxidants in liver of control and experimental animals
        
   
Groups
   
 SOD 
(Units min-1 
mg -1 
protein)
CAT
(µmoles of H2O2
consumed min -1 
mg -1 protein)
GPx  
(µmole of 
GSH oxidized 
min-1mg-1 
protein)
GR
(nmole of 
TNB  formed 
mg-1 protein 
min-1)
Group I
(Control) 8.59 ± 0.46 120.45 ± 3.89 11.75 ±0.52 6.29 ± 0.19
 Group II
(AZA)
 
5.03 ± 0.28a,* 48.04 ±  1.82a,* 4.19 ±  0.18a,* 3.36 ±  0.20a,*
   Group III
(QE) 8.50 ± 0.29NS 123.93 ±  5.65NS 12.11 ± 0.29NS 6.10 ±  0.34NS
 Group IV
(AZA+QE) 7.79 ± 0.43b,* 106.46 ±  3.47b,* 10.91 ± 0.40b,* 5.45 ±  0.28b,*
Results are expressed as mean ± S.D. for six rats. Units - SOD: Units min-1  mg-1 
protein;  CAT: µmoles  of H2O2 consumed min−1 mg−1 protein;  GPx: µmoles  of 
GSH  oxidized  min−1mg−1 protein;  GR:   nmoles  of  5-thio-2-nitrobenzoic  acid 
(TNB) formed mg-1 protein   min-1. 
Comparisons are made between: a-Group I and Group II; b-Group II and Group 
IV.
* Statistically significant (p < 0.05); NS – non-significant
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Fig. 15: Levels of SOD in the liver of the experimental animals and expressed as Units 
min-1   mg -1 protein. Results are given as mean ± S.D. for six rats. Comparisons are 
made  between:  a-Group I  and  Group II;  b-Group II  and  Group IV.    *  Statistically  
significant (p < 0.05); NS – non-significant. 
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Fig. 16: Levels of CAT in the liver of the experimental animals and expressed as µmoles 
of H2O2 consumed min  -1 mg  -1 protein. Results are given as mean ± S.D. for six rats. 
Comparisons are made between: a-Group I and Group II; b-Group II and Group IV.   *  
Statistically significant (p < 0.05); NS – non-significant.
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Fig. 17: Levels of GPx in the liver of the experimental animals and expressed as µmole 
of GSH oxidized min-1mg-1 protein.  Results  are given as mean ± S.D. for six rats. 
Comparisons are made between: a-Group I and Group II; b-Group II and Group IV.   *  
Statistically significant (p < 0.05); NS – non-significant. 
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Fig. 18: Levels of GR in the liver of the experimental animals and expressed as nmole of 
TNB  formed  mg-1 protein  min-1.  Results  are  given  as  mean  ±  S.D.  for  six  rats. 
Comparisons are made between: a-Group I and Group II; b-Group II and Group IV.   *  
Statistically significant (p < 0.05); NS – non-significant.
Table 4: Effect of Azathioprine and Quercetin on the activities of GSH and 
MDA in liver of control and experimental animals
Groups
GSH
(µmole
gm-1 tissue)
MDA
(µmole
mg-1 protein)
Group I
(Control)
 
4.72 ±0.23
 
3.5 ± 0.13
Group II
(AZA) 2.03 ± 0.14a,*
 
6.84 ± 0.38a,*
Group III
(QE)
 
4.87 ± 0.20NS 3.52 ± 0.12NS
Group IV
(AZA+QE)
  
4.65 ± 0.18b,*
 
4.18 ± 0.21b,*
Results are expressed as mean ± S.D. for 6 rats. Comparisons are made between: a-Group 
I and Group II; b-Group II and Group IV.    * Statistically significant (p < 0.05); NS – 
non-significant
Table 5: Effect of Azathioprine and Quercetin on Total Protein, DNA and 
RNA in liver of control and experimental animals
Groups
Total Protein
(mg/100mg 
tissue)
DNA
(µg/100mg tissue)
RNA
(µg/100mg 
tissue)
Group I
(Control) 13.00 ± 0.59 320.12 ± 14.72 509.48 ± 16.31
Group II
(AZA) 9.00 ± 0.28 195.76 ± 9.41 a,* 350.35 ±12.46 a,*
Group III
(QE) 12.60 ± 0.66 312.38 ± 13.96 NS 501.58 ± 17.74 NS
Group IV
(AZA+QE) 12.01 ± 0.55 276.00 ± 9.15 b,* 475.83 ± 18.86 b,*
Results are expressed as mean ± S.D. for 6 rats. Comparisons are made between: a-Group 
I and Group II; b-Group II and Group IV.    * Statistically significant (p < 0.05); NS – 
non-significant
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Fig.  19: Levels of  GSH in the liver of  the rats  and expressed as  µmole gm-1tissue. 
Results are given as mean ± S.D. for six rats. Comparisons are made between: a-Group I 
and Group II; b-Group II and Group IV.       * Statistically significant (p < 0.05); NS – 
non-significant.
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Fig. 20: Levels of MDA in the liver of the rats and expressed as  µmole mg-1  protein. 
Results are given as mean ± S.D. for six rats. Comparisons are made between: a-Group I 
and Group II; b-Group II and Group IV.       * Statistically significant (p < 0.05); NS – 
non-significant.
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Fig. 21: Levels of DNA in the liver of the rats and expressed as  µg/100 mg tissue. 
Results are given as mean ± S.D. for six rats. Comparisons are made between: a-Group I 
and Group II; b-Group II and Group IV.       * Statistically significant (p < 0.05); NS – 
non-significant.
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Fig. 22: Levels of RNA in the liver of the rats  and expressed as  µg/100 mg tissue. 
Results are given as mean ± S.D. for six rats. Comparisons are made between: a-Group I 
and Group II; b-Group II and Group IV.      * Statistically significant (p < 0.05); NS – 
non-significant.
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